The deletion of Gpr132 has been shown to ameliorate atherosclerosis, while the inhibition of the Src pathway using saracatinib presents a promising therapeutic strategy for addressing diabetic atherosclerosis. The gene discussed is SRC; the disease is atherosclerosis.